Update of the french drug reaction assessment method;Réactualisation de la méthode française d'imputabilité des effets indésirables des médicaments

Therapie

Volumn 66, Issue 6, 2011, Pages 517-525

  Arimone, Yannick ^a   Bidault, Irène ^b   Dutertre, Jean Paul ^c   Gérardin, Marie ^d   Guy, Claire ^e   Haramburu, Françoise ^f   Hillaire Buys, Dominique ^g   Meglio, Carmine ^h   Penfornis, Catherine ⁱ   Théophile, Hélène ^f   Valnet Rabier, Marie Blanche ^j  

^a Cellule Plan de Gestion de Risque   (France)

^b Département de Pharmacovigilance   (France)

^c Pharmacovigilance   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e Centre Régional de Pharmacovigilance et de Renseignement sur le Médicament   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h Laboratoire Lilly   (France)

ⁱ SANOFI   (France)

^j UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

Adverse drug reaction; Algorithm; Causality assessment; Drug safety

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; CLINICAL ASSESSMENT TOOL; DRUG INDUSTRY; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; STRENGTH;

EID: 84555218392     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2011073     Document Type: Article

References (12)

1. Daugoumau J, Evreux JC, Jouglard J. Méthode d'imputabilité des effets indésirables des médicaments. Therapie 1978; 33: 373-81 (Pubitemid 8366026)
2. Begaud B, Evreux JC, Jouglard J et al,. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985; 40: 111-8
3. Arrêté du 28 avril 2005 relatif aux bonnes pratiques de pharmacovigilance http://www.legifrance.gouv.fr
4. Théophile H, Arimone Y, Miremont-Salamé G et al,. Comparison of three methods (consensual expert judgment, algorithmic and probabilistic approaches) of routine causality assessment of adverse drug reactions: An assessment using reports made to a French pharmacovigilance centre. Drug Saf 2010; 33: 1045-54
5. Arimone Y, Bidault I, Collignon AE, et al. Update of the French causality assessment method: results of the validation phase. Abstracts: 10th ISoP Annual Meeting 'Pharmacovigilance in the Global Village'; 2010 Nov 3-6; Accra, Ghana. Drug Saf 2010; 33: 938 [Abstract 104]
6. Mockenhaupt M, Viboud C, Dunant A et al,. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44 (Pubitemid 350249390)
7. Bonhoeffer J, Bentsi-Enchill A, Chen RT et al,. Brighton collaboration methods working group. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009; 27: 2289-97
8. The Brighton Collaboration Website [homepage on the Internet]. 2010 Brighton Collaboration. Resources. [cited 2010 Sep 22]. https:// brightoncollaboration.org/public/resources.html
9. Larson AM, Polson J, Fontana RJ et al,. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-72 (Pubitemid 43260039)
10. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1991; 324: 169-74
11. Vandecasteele SJ, de Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010; 77: 760-4
12. Zucman D, de Truchis P, Majerholc C et al,. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed french HIV population. J Acquir Immune Defic Syndr 2007; 45: 1-3 (Pubitemid 46684436)